JP2021527711A - 神経系疾患および障害の改善のための方法 - Google Patents

神経系疾患および障害の改善のための方法 Download PDF

Info

Publication number
JP2021527711A
JP2021527711A JP2021519528A JP2021519528A JP2021527711A JP 2021527711 A JP2021527711 A JP 2021527711A JP 2021519528 A JP2021519528 A JP 2021519528A JP 2021519528 A JP2021519528 A JP 2021519528A JP 2021527711 A JP2021527711 A JP 2021527711A
Authority
JP
Japan
Prior art keywords
patient
disease
pabra
cognitive function
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021519528A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019241736A5 (https=
JP2021527711A5 (https=
Inventor
アンソニー ピー． フォード
Original Assignee
キュラセン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュラセン セラピューティクス インコーポレイテッド filed Critical キュラセン セラピューティクス インコーポレイテッド
Publication of JP2021527711A publication Critical patent/JP2021527711A/ja
Publication of JPWO2019241736A5 publication Critical patent/JPWO2019241736A5/ja
Publication of JP2021527711A5 publication Critical patent/JP2021527711A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021519528A 2018-06-14 2019-06-14 神経系疾患および障害の改善のための方法 Pending JP2021527711A (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201862685249P 2018-06-14 2018-06-14
US201862685246P 2018-06-14 2018-06-14
US201862685247P 2018-06-14 2018-06-14
US62/685,246 2018-06-14
US62/685,247 2018-06-14
US62/685,249 2018-06-14
US201862686660P 2018-06-18 2018-06-18
US201862686663P 2018-06-18 2018-06-18
US201862686658P 2018-06-18 2018-06-18
US62/686,663 2018-06-18
US62/686,658 2018-06-18
US62/686,660 2018-06-18
US201962825670P 2019-03-28 2019-03-28
US201962825702P 2019-03-28 2019-03-28
US201962825571P 2019-03-28 2019-03-28
US201962825675P 2019-03-28 2019-03-28
US62/825,571 2019-03-28
US62/825,670 2019-03-28
US62/825,675 2019-03-28
US62/825,702 2019-03-28
PCT/US2019/037358 WO2019241736A1 (en) 2018-06-14 2019-06-14 Methods for improving neurological diseases and disorders

Publications (3)

Publication Number Publication Date
JP2021527711A true JP2021527711A (ja) 2021-10-14
JPWO2019241736A5 JPWO2019241736A5 (https=) 2022-06-08
JP2021527711A5 JP2021527711A5 (https=) 2022-06-08

Family

ID=68842342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519528A Pending JP2021527711A (ja) 2018-06-14 2019-06-14 神経系疾患および障害の改善のための方法

Country Status (5)

Country Link
EP (1) EP3806847A4 (https=)
JP (1) JP2021527711A (https=)
AU (1) AU2019287771A1 (https=)
CA (1) CA3100848A1 (https=)
WO (1) WO2019241736A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541379A (ja) * 2020-09-01 2023-10-02 キュラセン セラピューティクス インコーポレイテッド 神経系の疾患及び障害を改善するための組成物及び方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
EP4651867A1 (en) 2023-01-20 2025-11-26 Atrogi AB Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281607A (en) * 1992-10-08 1994-01-25 New York University Method of using Alpha 2-Antagonists for the Treatment of Neurodegenerative Diseases
US20130096126A1 (en) * 2010-04-22 2013-04-18 The Board Of Trustees Of The Leland Stanford Junior University Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
US20140235726A1 (en) * 2013-02-13 2014-08-21 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248984A1 (en) * 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
US9265735B2 (en) * 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
KR20160026897A (ko) * 2013-06-27 2016-03-09 세다르스-신나이 메디칼 센터 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281607A (en) * 1992-10-08 1994-01-25 New York University Method of using Alpha 2-Antagonists for the Treatment of Neurodegenerative Diseases
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
US20130096126A1 (en) * 2010-04-22 2013-04-18 The Board Of Trustees Of The Leland Stanford Junior University Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
US20140235726A1 (en) * 2013-02-13 2014-08-21 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541379A (ja) * 2020-09-01 2023-10-02 キュラセン セラピューティクス インコーポレイテッド 神経系の疾患及び障害を改善するための組成物及び方法

Also Published As

Publication number Publication date
EP3806847A1 (en) 2021-04-21
EP3806847A4 (en) 2022-05-04
CA3100848A1 (en) 2019-12-19
WO2019241736A1 (en) 2019-12-19
AU2019287771A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
US12558325B2 (en) Methods for improving neurological diseases and disorders
JP2021527712A (ja) 神経系疾患および障害を、診断、監視、および治療するための方法
JP2021527711A (ja) 神経系疾患および障害の改善のための方法
ES2327521T3 (es) Procedimientos de prevencion, tratamiento y diagnostico de trastornos de la agregacion de proteinas.
KR102171747B1 (ko) 알츠하이머 병 치료를 위한 방법 및 약품
JP5733715B2 (ja) 経鼻中枢神経系組織標識用組成物、経鼻中枢神経系組織標識用組成物を用いた標識方法及びスクリーニング方法
US20230263749A1 (en) Compositions and methods for improving neurological diseases and disorders
Arime et al. Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice
EP2198040B1 (en) In vivo imaging of myelin
US9072746B2 (en) Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
US20250134835A1 (en) Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)
US20210251923A1 (en) Methods for improving neurological diseases and disorders
US20230157974A1 (en) Compositions and methods for improving neurological diseases and disorders
CN116801875A (zh) 用于改善神经疾病和病症的组合物和方法
WO2025188807A1 (en) Combination compositions and methods of use
Salcin Neuroepigenetics of Cocaine Use: A Positron Emission Tomography Study of Histone Deacetylase Expression in People Who Use Cocaine
ES2832549T3 (es) Composiciones y métodos para tratar la esclerosis lateral amiotrófica en respondedores
Leuzy In Vivo Quantification of Glutamatergic Abnormalities in Behavioral Variant Frontotemporal Dementia
WO2016179117A1 (en) Composition and method for detecting hypoxia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231204